Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers.

Trial Profile

Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs ISIS 353512 (Primary) ; ISIS 353512 (Primary)
  • Indications Cardiovascular disorders; Rheumatic disorders
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 17 Feb 2010 Planned number of patients changed from 58 to 125 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top